{"id":"W3030929389","doi":"10.1200/jco.2020.38.15_suppl.1006","title":"Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with <i>PIK3CA-</i>mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Fulvestrant; Internal medicine; Metastatic breast cancer; Clinical endpoint; Cohort; Breast cancer; Letrozole; Oncology; Cancer; Clinical trial; Estrogen receptor; Tamoxifen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008034953,0.0005510298,0.0008735686,0.0002306338,0.0001567175,0.0006229131,0.000342659,0.0005130911,0.002598033],"category_scores_gemma":[0.0005093886,0.0002143461,0.001143207,0.0002936406,0.0003271468,0.0005915352,0.0002980846,0.00155942,0.0005048188],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005241055,"about_ca_system_score_gemma":0.0005757087,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005429232,"about_ca_topic_score_gemma":0.001839881,"domain_scores_codex":[0.9997794,0.0001109872,0.00001494652,0.00003200421,0.00001965324,0.00004300915],"domain_scores_gemma":[0.9996185,0.00007971233,0.00009106439,0.00002323959,0.00001741641,0.0001700463],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.791698,0.01277776,0.0208007,0.0009326394,0.001832995,0.0001941724,0.0001577682,0.001937561,0.01826936,0.0002797788,0.003212922,0.1479063],"study_design_scores_gemma":[0.3829438,0.5512611,0.04677553,0.0001669008,0.001865739,0.0006945785,0.0001415254,0.001753832,0.005104074,0.0005332836,0.008720241,0.0000394555],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9915024,0.004586473,0.0002471694,0.0003289166,0.00007365212,0.0004125956,0.000786013,0.00004173566,0.002021086],"genre_scores_gemma":[0.993865,0.002402121,0.0004091265,0.0004153831,0.00009027209,0.0003115078,0.001532751,0.00001029123,0.0009636083],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002598033,"threshold_uncertainty_score":0.008691311,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03321510135610873,"score_gpt":0.362653915720541,"score_spread":0.3294388143644323,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}